Journal articles

Conference proceedings papers

  • Carroll C, Kaltenthaler E, Tappenden P, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M & Woolacott N (2016) THE ROLE AND IMPACT OF EVIDENCE REVIEW GROUP ANALYSES IN THE NICE SINGLE TECHNOLOGY ASSESSMENT (STA) PROCESS. VALUE IN HEALTH, Vol. 19(7) (pp A468-A469)
  • Alshreef AO (2016) Conceptual Modelling for Cost-Effectiveness Analysis of Intravitreal Therapy with Ranibizumab, Aflibercept or Bevacizumab for Macular Oedema Due to Central Retinal Vein Occlusion. Value in Health, Vol. 19(7) View this article in WRRO
  • Harnan S, Essat M, Gomersall T, Tappenden P, Wong R, Lawson R, Pavord I & Everard M (2015) Exhaled Nitric Oxide For The Diagnosis Of Asthma In Adults And Children: A Systematic Review. Value in Health, Vol. 18(7) (pp A345-A345)
  • Tappenden P, Harnan S, Uttley L, Mildred M, Taylor CJ, Brownlee K & Walshaw M (2013) THE COST-EFFECTIVENESS OF DRY POWDER ANTIBIOTICS FOR THE TREATMENT OF PSEUDOMONAS AERUGINOSA IN PATIENTS WITH CYSTIC FIBROSIS. VALUE IN HEALTH, Vol. 16(7) (pp A372-A372)
  • Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad E, Buyse M & Taylor R (2013) VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMOURS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. VALUE IN HEALTH, Vol. 16(7) (pp A327-A327)
  • Harnan SE, Uttley L, Cantrell A, Taylor CJ, Walshaw M, Brownlee K & Tappenden P (2013) SYSTEMATIC REVIEW OF COLISTIMETHATE SODIUM DRY POWDER AND TOBRAMYCIN DRY POWDER ANTIBIOTICS FOR PSEUDOMONAS AERUGINOSA LUNG INFECTION IN CYSTIC FIBROSIS. VALUE IN HEALTH, Vol. 16(7) (pp A367-A367)
  • Kaltenthaler E, Rathbone J, Tappenden P, Bessey A & Cantrell A (2012) PUK2 Issues in the Systematic Review of Drugs for Rare Diseases: A Case Study of Eculizumab for aHUS. Value in Health, Vol. 15(7) (pp A455-A455)
  • Kaltenthaler E, Rathbone J, Tappenden P, Bessey A & Cantrell A (2012) ISSUES IN THE SYSTEMATIC REVIEW OF DRUGS FOR RARE DISEASES: A CASE STUDY OF ECULIZUMAB FOR AHUS. VALUE IN HEALTH, Vol. 15(7) (pp A455-A455)
  • Tappenden P, Brennan A, Chilcott J & Squires H (2011) A METHODOLOGICAL FRAMEWORK FOR DEVELOPING MODELS OF WHOLE DISEASE AREAS TO INFORM RESOURCE ALLOCATION DECISIONS. VALUE IN HEALTH, Vol. 14(7) (pp A243-A243)
  • Tappenden P, Brennan A, Chilcott J & Squires H (2011) USING WHOLE DISEASE MODELLING TO INFORM ECONOMIC RECOMMENDATIONS FOR THE DETECTION, DIAGNOSIS, TREATMENT AND FOLLOW-UP OF COLORECTAL CANCER. VALUE IN HEALTH, Vol. 14(7) (pp A469-A470)
  • Delea TE, Tappenden P, Sofrygin O, Karnon J, Amonkar M, Browning D, Rudge H & Walker M (2007) Cost-effectiveness (CE) of lapatinib plus capecitabine (L plus C) in women with ErbB2+(HER2+) metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the United Kingdom (UK) National Health Service (NHS) perspective. EJC SUPPLEMENTS, Vol. 5(4) (pp 225-225)

Scholarly editions

  • Tappenden P, Brazier J & Ratcliffe J Does the National Institute for Health and Clinical Excellence take account of factors such as uncertainty and equity as well as incremental cost-effectiveness in commissioning health care services? A binary choice experiment.
  • Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z, Tappenden P & Wailoo A A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence.